Collplant Holdings Ltd (CLGN) received a Buy rating and a $7 price target from H.C. Wainwright analyst Swayampakula Ramakanth today. The company’s shares opened today at $4.98.
Ramakanth commented:
“We are initiating coverage of CLGN with 12-month price target of $7.00 per ADS. We derive our price target based on a risk-adjusted NPV analysis of projected Vergenix, dermal filler, and BioInk revenues through 2030 assuming a 12.6% discount rate and 3% terminal growth rate.”
According to TipRanks.com, Ramakanth is ranked 0 out of 5 stars with an average return of -2.8% and a 33.0% success rate. Ramakanth covers the Healthcare sector, focusing on stocks such as Diffusion Pharmaceuticals Inc, IntelGenx Technologies, and Tyme Technologies Inc.
Currently, the analyst consensus on Collplant Holdings Ltd is a Moderate Buy with an average price target of $7.
See today’s analyst top recommended stocks >>
Based on Collplant Holdings Ltd’s latest earnings release for the quarter ending September 30, the company reported a quarterly GAAP net loss of $1.33 million. In comparison, last year the company had a GAAP net loss of $1.1 million.
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
Collplant Holdings Ltd. is a regenerative medicine company. It engages in the research, development, manufacture and marketing of medical products for tissue repair, initially for orthobiologics and advanced wound care markets. The company’s products include VergenixSTR, VergenixFG, CollPlant Surgical Matrix.
